Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:35:52.693Z.
Calculation as of: 2026-10-06T20:35:52.693Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e9e072c721023a8f5b36c3f5b81ac18026d6678c99aa2a087bce1e48ab153e53
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$4.72M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.86M
Price/OCF Ratio
N/A
TTM Avg
11.16
3Y Avg
11.16
5Y Avg
11.16
Market Cap
$4.97M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.40M
Price/OCF Ratio
N/A
TTM Avg
35.59
3Y Avg
35.59
5Y Avg
35.59
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CalciMedica, Inc. (CALC) | $4.69M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $4.71M | N/A | 15.43 | 17.34 | 17.34 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A | N/A | N/A | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.53M | N/A | N/A | N/A | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | N/A | 11.16 | 11.16 | 11.16 |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.40M | N/A | 35.59 | 35.59 | 35.59 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
